William Blair Brokers Boost Earnings Estimates for DVAX

Dynavax Technologies Co. (NASDAQ:DVAX) – Analysts at William Blair lifted their Q4 2024 earnings estimates for shares of Dynavax Technologies in a research note issued on Monday, January 13th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings per share of $0.02 for the quarter, up from their prior forecast of $0.01. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share. William Blair also issued estimates for Dynavax Technologies’ FY2026 earnings at $0.48 EPS.

Several other brokerages have also commented on DVAX. HC Wainwright boosted their price target on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Tuesday.

Dynavax Technologies Stock Down 0.7 %

DVAX stock opened at $12.39 on Thursday. Dynavax Technologies has a 52 week low of $9.74 and a 52 week high of $14.30. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.63 billion, a P/E ratio of 95.32 and a beta of 1.34. The company’s 50-day moving average price is $12.78 and its 200 day moving average price is $11.66.

Institutional Trading of Dynavax Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new position in shares of Dynavax Technologies during the 2nd quarter worth approximately $17,615,000. Great Point Partners LLC increased its position in Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock worth $26,660,000 after buying an additional 1,109,080 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Dynavax Technologies in the third quarter worth $8,291,000. PDT Partners LLC purchased a new stake in shares of Dynavax Technologies in the third quarter valued at $3,967,000. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Dynavax Technologies during the second quarter valued at $3,144,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.